Compare Neurocrine Biosciences Inc (NBIX) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Newegg Commerce Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Newegg Commerce Inc trades at $14.93 (market cap $315.87M). The key difference: Neurocrine Biosciences Inc is far larger — about 49.9× Newegg Commerce Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | NEGG | |
|---|---|---|
Market Cap | $15.77B | $315.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $92.74 |
52-Week Low | $123.10 | $12.87 |
Enterprise Value | $15.78B | $286.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
NEGG trades at $15.17, down 0.98% on the day, with a bearish technical signal from moving averages but recent earnings beats showing improvement. The company reported Q2 2026 EPS of $0.11, beating expectations by $0.51, while revenue trends show stabilization after declines from 2022-2024. Valuation metrics include a P/E of 33.27 and P/S of 0.23, with improving profitability margins.
The outlook suggests cautious optimism as NEGG demonstrates operational improvement with four consecutive earnings beats and positive net income projected for 2026. Key risks include negative operating cash flow and competitive e-commerce pressures, while the single analyst coverage maintains a Buy rating with 100% consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
